RYTM vs. VRNA

Last updated Jun 9, 2026

RYTM (Rhythm Pharmaceuticals, Inc.) and VRNA (Verona Pharma plc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.18 correlation, their price movements are largely independent.

Performance

RYTM vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rhythm Pharmaceuticals, Inc. (RYTM) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RYTM

• 1D: -0.55%
• 1M: -8.76%
• YTD: -19.73%
• 6M: -18.31%
• 1Y: 26.16%
• 3Y*: 70.19%
• 5Y*: 35.24%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RYTM vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RYTM Rhythm Pharmaceuticals, Inc.	-19.73%	91.21%	21.78%	57.86%	191.78%	-66.43%	29.49%	-14.58%	-7.50%	25.20%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-23.41%

Correlation

The correlation between RYTM and VRNA is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.02
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.23
Correlation (All Time) Calculated using the full available price history since Oct 5, 2017	0.18

The correlation between RYTM and VRNA shifts across timeframes, from -0.02 (1 year) to 0.23 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap RYTM : $5.84B VRNA : $9.72B
EPS RYTM : -$3.10 VRNA : -$0.69
PS Ratio RYTM : 26.00 VRNA : 57.97
PB Ratio RYTM : 712.63 VRNA : 34.92
Total Revenue (TTM) RYTM : $217.17M VRNA : $167.65M
Gross Profit (TTM) RYTM : $194.16M VRNA : $159.52M
EBITDA (TTM) RYTM : -$182.86M VRNA : -$40.86M

Return for Risk

RYTM vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RYTM

RYTM Risk / Return Rank: 60
RYTM Sharpe Ratio Rank: 58
RYTM Sortino Ratio Rank: 62
RYTM Omega Ratio Rank: 59
RYTM Calmar Ratio Rank: 59
RYTM Martin Ratio Rank: 59

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RYTM vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RYTM	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.46	—	—
Sortino ratio: Return per unit of downside risk	1.27	—	—
Omega ratio: Gain probability vs. loss probability	1.15	—	—
Calmar ratio: Return relative to maximum drawdown	0.74	—	—
Martin ratio: Return relative to average drawdown	1.74	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	RYTM	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.46	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.46	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.18	—	—

Drawdowns

Drawdown Indicators

	RYTM	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-92.10%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-35.54%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-35.54%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-85.49%	—	—
Current Drawdown Current decline from peak	-26.95%	—	—
Average Drawdown Average peak-to-trough decline	-32.18%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	15.08%	—	—

Volatility

Volatility by Period

	RYTM	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.47%	—	—
Volatility (6M) Calculated over the trailing 6-month period	36.66%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	57.36%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.40%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.96%	—	—

Dividends

RYTM vs. VRNA - Dividend Comparison

Neither RYTM nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

RYTM vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Rhythm Pharmaceuticals, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RYTM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a gross profit of 52.96M and revenue of 60.11M. Therefore, the gross margin over that period was 88.1%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

RYTM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported an operating income of -52.36M and revenue of 60.11M, resulting in an operating margin of -87.1%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

RYTM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a net income of -56.74M and revenue of 60.11M, resulting in a net margin of -94.4%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both RYTM and VRNA in my portfolio?

RYTM and VRNA have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.